MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Launched by NATIONAL CANCER INSTITUTE (NCI) · Sep 29, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The MYELOMATCH trial is a research study designed to help people with certain types of blood cancers, specifically acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The main goal of this study is to use special tests on patients' blood and bone marrow to identify specific markers, which are substances in the body that can provide important information about the cancer. By understanding these markers, doctors can determine whether patients qualify for clinical trials that test new treatments or if they should continue with standard treatment options.
To be eligible for this trial, participants must be at least 18 years old and suspected of having untreated AML or MDS. Importantly, they should not have received prior cancer treatments, although some medications to control blood cell counts may be allowed. If someone joins the study, they can expect to undergo testing to check for these markers, and their results will help guide their treatment options. Additionally, the trial offers the opportunity for participants to contribute to research by providing samples for further study. This trial is currently recruiting participants, and it aims to ensure that patients receive the best possible care based on their individual cancer characteristics.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants must be suspected to have previously untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Participants with AML cannot have a history of previously treated myeloproliferative neoplasms (MPN) or MDS.
- • Participants must be \>= 18 years of age.
- • Participants must not have received prior anti-cancer therapy for AML or MDS.
- • Note: Hydroxyurea to control the white blood cell count (WBC) is allowed.
- • Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility. Participants must not be currently receiving any cytarabine-containing therapy other than up to 1 g/m\^2 of cytarabine, which is allowed for urgent cytoreduction.
- • Participants are allowed prior use of hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide, with a maximum limit of 1 month of exposure.
- • Note: Participants receiving hydroxyurea prior to treatment substudy or TAP assignment must agree to discontinue hydroxyurea within 24 hours before beginning substudy or TAP treatment.
- • Participants must not have a prior or concurrent malignancy that requires concurrent anti-cancer therapy
- • Note: active hormonal therapy is allowed
- • Participants must have a Zubrod Performance Status evaluation within 28 days prior to registration.
- • Participants must agree to have translational medicine specimens submitted.
- • Participants must be offered the opportunity to participate in specimen banking.
- • Note: Specimens must be collected and submitted following the initial paper-based process and subsequently via the Precision Medicine Specimen Tracking Forms in Medidata Rave instance for the MyeloMATCH MSRP.
- • Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines.
- • Note: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
- • The master screening and reassessment protocol (MSRP) should only be used in sites where the relevant AML treatment substudies are open or if the site is willing to follow the MSRP Tier Advancement Pathway (TAP) for patients in the event that the site does not have the relevant study open and transfer to another site that does have the study open. For example, if a site does not have a myeloMATCH Tier 1 study for older AML open for enrollment, such older AML patients should only be consented for the MSRP if the site is willing to treat the patient with standard of care on TAP or is willing to transfer the patient to a center with a study open that the patient would otherwise match to.
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Durham, North Carolina, United States
Cleveland, Ohio, United States
Milwaukee, Wisconsin, United States
Saint Louis, Missouri, United States
Flint, Michigan, United States
Providence, Rhode Island, United States
Flint, Michigan, United States
Edina, Minnesota, United States
Maywood, Illinois, United States
Peoria, Illinois, United States
Detroit, Michigan, United States
Toms River, New Jersey, United States
Calgary, Alberta, Canada
Hamilton, Ontario, Canada
Manhasset, New York, United States
Little Rock, Arkansas, United States
Winnipeg, Manitoba, Canada
Oklahoma City, Oklahoma, United States
La Crosse, Wisconsin, United States
New York, New York, United States
Long Branch, New Jersey, United States
Saint Paul, Minnesota, United States
Kalispell, Montana, United States
Charlottesville, Virginia, United States
Rochester, New York, United States
Salina, Kansas, United States
Coon Rapids, Minnesota, United States
Urbana, Illinois, United States
Minneapolis, Minnesota, United States
Effingham, Illinois, United States
Lawrence, Kansas, United States
Saint Joseph, Missouri, United States
Springfield, Illinois, United States
Houston, Texas, United States
Portland, Oregon, United States
Springfield, Illinois, United States
Boston, Massachusetts, United States
Rochester, New York, United States
Danville, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Salt Lake City, Utah, United States
Birmingham, Alabama, United States
Tucson, Arizona, United States
Sacramento, California, United States
Jacksonville, Florida, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Iowa City, Iowa, United States
Topeka, Kansas, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Detroit, Michigan, United States
Duluth, Minnesota, United States
Saint Louis, Missouri, United States
Omaha, Nebraska, United States
New Brunswick, New Jersey, United States
New York, New York, United States
Syracuse, New York, United States
Chapel Hill, North Carolina, United States
Winston Salem, North Carolina, United States
Winston Salem, North Carolina, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Knoxville, Tennessee, United States
Burlington, Vermont, United States
Lexington, Kentucky, United States
Charlotte, North Carolina, United States
Allentown, Pennsylvania, United States
Falls Church, Virginia, United States
Evanston, Illinois, United States
Saint Louis Park, Minnesota, United States
Livingston, New Jersey, United States
Memphis, Tennessee, United States
San Juan, , Puerto Rico
Louisville, Kentucky, United States
Milwaukee, Wisconsin, United States
Oakland, California, United States
Albuquerque, New Mexico, United States
Charlotte, North Carolina, United States
Sioux Falls, South Dakota, United States
Houston, Texas, United States
Richmond, Virginia, United States
San Francisco, California, United States
Augusta, Georgia, United States
Rochester, Minnesota, United States
Bronx, New York, United States
Green Bay, Wisconsin, United States
Marshfield, Wisconsin, United States
Portland, Oregon, United States
Decatur, Illinois, United States
Ottawa, Illinois, United States
Peoria, Illinois, United States
Peoria, Illinois, United States
Missoula, Montana, United States
Des Moines, Iowa, United States
Los Angeles, California, United States
Wilkes Barre, Pennsylvania, United States
Fremont, California, United States
Roseville, California, United States
Sacramento, California, United States
San Francisco, California, United States
San Jose, California, United States
San Leandro, California, United States
Santa Clara, California, United States
Santa Rosa, California, United States
South San Francisco, California, United States
Vallejo, California, United States
Walnut Creek, California, United States
Galesburg, Illinois, United States
Kansas City, Kansas, United States
Topeka, Kansas, United States
Worcester, Massachusetts, United States
Billings, Montana, United States
West Reading, Pennsylvania, United States
Sioux Falls, South Dakota, United States
Burlington, Vermont, United States
Green Bay, Wisconsin, United States
Oconomowoc, Wisconsin, United States
Oconto Falls, Wisconsin, United States
Rice Lake, Wisconsin, United States
Sheboygan, Wisconsin, United States
Waukesha, Wisconsin, United States
West Allis, Wisconsin, United States
Weston, Wisconsin, United States
Berkeley, California, United States
Toronto, Ontario, Canada
Greenfield Park, Quebec, Canada
Livonia, Michigan, United States
Newberg, Oregon, United States
Oshkosh, Wisconsin, United States
Montreal, Quebec, Canada
Boise, Idaho, United States
Tucson, Arizona, United States
Honolulu, Hawaii, United States
Canton, Illinois, United States
Carthage, Illinois, United States
Eureka, Illinois, United States
Kewanee, Illinois, United States
Macomb, Illinois, United States
Peru, Illinois, United States
Princeton, Illinois, United States
Boise, Idaho, United States
Appleton, Wisconsin, United States
Warrenville, Illinois, United States
Lake Success, New York, United States
Grafton, Wisconsin, United States
Greenville, South Carolina, United States
Portland, Oregon, United States
Post Falls, Idaho, United States
Bloomington, Illinois, United States
Geneva, Illinois, United States
Pekin, Illinois, United States
Saint Louis, Missouri, United States
Boiling Springs, South Carolina, United States
Easley, South Carolina, United States
Greenville, South Carolina, United States
Greenville, South Carolina, United States
Greer, South Carolina, United States
Seneca, South Carolina, United States
Burlington, Wisconsin, United States
Germantown, Wisconsin, United States
Green Bay, Wisconsin, United States
Kenosha, Wisconsin, United States
Marinette, Wisconsin, United States
Milwaukee, Wisconsin, United States
Racine, Wisconsin, United States
Summit, Wisconsin, United States
Two Rivers, Wisconsin, United States
Wauwatosa, Wisconsin, United States
Bloomington, Illinois, United States
Olathe, Kansas, United States
Saint Louis, Missouri, United States
Montreal, Quebec, Canada
Fresno, California, United States
Modesto, California, United States
Fruitland, Idaho, United States
Meridian, Idaho, United States
Nampa, Idaho, United States
Overland Park, Kansas, United States
Kansas City, Missouri, United States
Lee's Summit, Missouri, United States
Oregon City, Oregon, United States
Edmonds, Washington, United States
Issaquah, Washington, United States
Springfield, Illinois, United States
Saint Peters, Missouri, United States
Fairfax, Virginia, United States
Great Falls, Montana, United States
Caldwell, Idaho, United States
Coeur D'alene, Idaho, United States
Farmington Hills, Michigan, United States
Flint, Michigan, United States
Flint, Michigan, United States
Anaconda, Montana, United States
Las Vegas, Nevada, United States
Commack, New York, United States
Decatur, Illinois, United States
Effingham, Illinois, United States
Mattoon, Illinois, United States
O'fallon, Illinois, United States
Louisville, Kentucky, United States
Brighton, Michigan, United States
Canton, Michigan, United States
Chelsea, Michigan, United States
Novi, Michigan, United States
West Bloomfield, Michigan, United States
Ypsilanti, Michigan, United States
Sainte Genevieve, Missouri, United States
Sullivan, Missouri, United States
Sturgeon Bay, Wisconsin, United States
Montvale, New Jersey, United States
Uniondale, New York, United States
Middletown, New Jersey, United States
New Haven, Connecticut, United States
Glenview, Illinois, United States
Highland Park, Illinois, United States
Basking Ridge, New Jersey, United States
Dublin, California, United States
Sacramento, California, United States
San Rafael, California, United States
Baton Rouge, Louisiana, United States
Columbus, Mississippi, United States
Grenada, Mississippi, United States
New Albany, Mississippi, United States
Oxford, Mississippi, United States
Southhaven, Mississippi, United States
Creve Coeur, Missouri, United States
Saint Louis, Missouri, United States
Henderson, Nevada, United States
Eau Claire, Wisconsin, United States
Milwaukee, Wisconsin, United States
Mukwonago, Wisconsin, United States
Waukesha, Wisconsin, United States
Overland Park, Kansas, United States
Westwood, Kansas, United States
South Portland, Maine, United States
Phoenix, Arizona, United States
Fairway, Kansas, United States
Las Vegas, Nevada, United States
Seattle, Washington, United States
Dekalb, Illinois, United States
Stevens Point, Wisconsin, United States
West Haven, Connecticut, United States
Deer River, Minnesota, United States
Hibbing, Minnesota, United States
Virginia, Minnesota, United States
Collierville, Tennessee, United States
Ashland, Wisconsin, United States
Long Beach, California, United States
Bellevue, Nebraska, United States
Omaha, Nebraska, United States
Lake Forest, Illinois, United States
Portland, Oregon, United States
Madison, Wisconsin, United States
Dixon, Illinois, United States
Washington, Illinois, United States
Baton Rouge, Louisiana, United States
Farmington, Missouri, United States
San Juan, , Puerto Rico
Bozeman, Montana, United States
Baton Rouge, Louisiana, United States
Cudahy, Wisconsin, United States
Paramus, New Jersey, United States
Missoula, Montana, United States
Salt Lake City, Utah, United States
Springfield, Illinois, United States
Sheboygan, Wisconsin, United States
Wilmington, North Carolina, United States
Kansas City, Missouri, United States
Des Moines, Iowa, United States
Kalispell, Montana, United States
Nampa, Idaho, United States
Ann Arbor, Michigan, United States
Danville, Illinois, United States
Orland Park, Illinois, United States
Minocqua, Wisconsin, United States
Brunswick, Maine, United States
Glenview, Illinois, United States
Grayslake, Illinois, United States
Sunset Hills, Missouri, United States
Clive, Iowa, United States
Hays, Kansas, United States
Madison, Wisconsin, United States
Ridgewood, New Jersey, United States
Sandpoint, Idaho, United States
Ontario, Oregon, United States
Madison, Wisconsin, United States
Flint, Michigan, United States
Calgary, Alberta, Canada
Olathe, Kansas, United States
Clive, Iowa, United States
Des Moines, Iowa, United States
Calgary, Alberta, Canada
South Portland, Maine, United States
Portland, Maine, United States
Patients applied
Trial Officials
Jerald P Radich
Principal Investigator
SWOG Cancer Research Network
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials